The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-25 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
=== Enzyme profiling === Identification of substrates for orphan enzymes Optimization of known enzyme substrates Elucidation of signal transduction pathways Detection of contaminating enzyme activities Consensus sequence and key residues determination Identifying sites for protein-protein interactions within a complex
Opium contains two main groups of alkaloids. Phenanthrenes such as morphine, codeine, and thebaine are the main psychoactive constituents. Isoquinolines such as papaverine and noscapine have no significant central nervous system effects. Morphine is the most prevalent and important alkaloid in opium, consisting of 10–16 percent of the total, and is responsible for most of its harmful effects such as lung edema, respiratory difficulties, coma, or cardiac or respiratory collapse. Morphine binds to and activates mu opioid receptors in the brain, spinal cord, stomach and intestine. Regular use can lead to drug tolerance or physical dependence. Chronic opium addicts in 1906 China consumed an average of eight grams of opium daily; opium addicts in modern Iran are thought to consume about the same. Both analgesia and drug addiction are functions of the mu opioid receptor, the class of opioid receptor first identified as responsive to morphine. Tolerance is associated with the superactivation of the receptor, which may be affected by the degree of endocytosis caused by the opioid administered, and leads to a superactivation of cyclic AMP signaling. Long-term use of morphine in palliative care and the management of chronic pain always entails a risk that the patient develops tolerance or physical dependence. There are many kinds of rehabilitation treatment, including pharmacologically based treatments with naltrexone, methadone, or ibogaine.
== Medical uses == Luspatercept is indicated for the treatment of adults with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. Luspatercept is indicated for the treatment of adults with transfusion-dependent anaemia associated with beta thalassaemia.
Sources: en.wikipedia.org
If the TP53 gene is damaged, its ability to suppress tumors is severely compromised. Individuals who inherit only one functional copy of TP53 are predisposed to developing tumors in early adulthood, a condition known as Li–Fraumeni syndrome. The TP53 gene can also be altered by mutagens—such as chemicals, radiation, or certain viruses—thereby increasing the likelihood of uncontrolled cell division. More than 50 percent of human tumors harbor a mutation or deletion of the TP53 gene. Loss of p53 function leads to genomic instability, frequently resulting in an aneuploidy phenotype. Certain pathogens can also disrupt p53 activity. For example, human papillomavirus (HPV) produces the viral protein E6, which binds to and inactivates p53. In conjunction with the HPV protein E7, which inactivates the cell cycle regulator pRb, this promotes repeated cell division, clinically presenting as warts. High-risk HPV types, particularly types 16 and 18, can drive the progression from benign warts to low- or high-grade cervical dysplasia, reversible precancerous lesions. Persistent cervical infection can lead to irreversible changes, including carcinoma in situ and invasive cervical cancer. These outcomes are primarily driven by viral integration into the host genome and the continued expression of the E6 and E7 oncoproteins.
== Prevention == Preventing recurrence of hyperkalemia typically involves reduction of dietary potassium, removal of an offending medication, and/or the addition of a diuretic (such as furosemide or hydrochlorothiazide). Sodium polystyrene sulfonate and sorbitol (combined as Kayexalate) are occasionally used on an ongoing basis to maintain lower serum levels of potassium, though the safety of long-term use of sodium polystyrene sulfonate for this purpose is not well understood. High dietary sources include meat, chicken, seafood, vegetables such as avocados, tomatoes and potatoes, fruits such as bananas, oranges and nuts.
==== Vitamin K ==== Vitamin K is an essential factor to the hepatic gamma-glutamyl carboxylase that adds a carboxyl group to glutamic acid residues on factors II, VII, IX and X, as well as Protein S, Protein C and Protein Z. In adding the gamma-carboxyl group to glutamate residues on the immature clotting factors, Vitamin K is itself oxidized. Another enzyme, Vitamin K epoxide reductase (VKORC), reduces vitamin K back to its active form. Vitamin K epoxide reductase is pharmacologically important as a target of anticoagulant drugs warfarin and related coumarins such as acenocoumarol, phenprocoumon, and dicumarol. These drugs create a deficiency of reduced vitamin K by blocking VKORC, thereby inhibiting maturation of clotting factors. Vitamin K deficiency from other causes (e.g., in malabsorption) or impaired vitamin K metabolism in disease (e.g., in liver failure) lead to the formation of PIVKAs (proteins formed in vitamin K absence), which are partially or totally non-gamma carboxylated, affecting the coagulation factors' ability to bind to phospholipid.
== Early life == Carrey was born in Newmarket, Ontario, Canada, to Kathleen (née Oram), a homemaker, and Percy Carrey, a musician and accountant. He was raised Catholic and had three older siblings. His mother was of Irish and Scottish descent, and his father was of French-Canadian ancestry; the family's original surname was Carré. At age eight, he began making faces before a mirror and discovered a talent for doing impressions. At age ten, Carrey wrote a letter to Carol Burnett of the Carol Burnett Show pointing out that he was already a master of impressions and should be considered for a role on the show; he was overjoyed when he received a form letter reply. A fan of Monty Python, whose television show Monty Python's Flying Circus aired in the 1970s, in 2014 Carrey appeared on Monty Python's Best Bits (Mostly) and recalled the effect on him of Ernest Scribbler (played by Michael Palin) laughing himself to death in "The Funniest Joke in the World" sketch. Radio Times states, "You'll see why immediately: Palin's performance is uncannily Carreyesque." Carrey spent his early years in the borough of Scarborough, Ontario, part of Metropolitan Toronto, where he attended Blessed Trinity Catholic Elementary School in North York. His family later moved to Burlington, Ontario, where they would spend eight years; Carrey attended Aldershot High School while there. Some time later, his family became homeless and lived together in a Volkswagen van while teenage Carrey and his brother spent months living in a tent in Charles Daley Park on the Lake Ontario shore in Lincoln, Ontario.
Sources: en.wikipedia.org
==== Formation of the neurotransmitter gamma-aminobutyric acid ==== A study conducted on the GABAergic neurons (i.e., nerve cells) in the neocortex of rat brains reported that the cytosolic form of the aspartate transaminase enzyme metabolizes α-ketoglutarate to glutamate which in turn is metabolized by glutamic acid decarboxylase to the inhibitory neurotransmitter gamma-aminobutyric acid. These metabolic reactions occur at the ends of the inhibitory axons of the GABAergic neurons and result in the release of gamma-aminobutyric acid which then inhibits the activation of nearby neurons.
The CAP has three main parts. First, the European Agricultural Guarantee Fund distributes 'direct payments', which are 70.9% of the CAP budget. The Direct Payments Regulation 2013 gives payments to an 'active farmer' that carries out agricultural activity, grazing or cultivation, does not operate airports, rail, waterworks, real estate, sport or recreation grounds, and has the land at their disposal. The farm must have at least 1 hectare and receive €100 for each, though member states can set higher thresholds (e.g. 5 hectares and €200). If payments reach over €150,000 there is a 5% reduction per hectare for each hectare. This favours large farm corporations, and the largest 1% typically receive around 10 to 15% of all subsidies in member states. As conditions of receiving subsidies, farms can be required to keep land in good condition, for public, animal, and plant health, and maintain environment standards. For minimal biodiversity, farmers must have over two crops if they have 10 hectares, not farm at least 5% of lintensively (an 'ecological focus area' over 15 hectares, and have three crops over 30 hectares. Environmentally sensitive grasslands, as designated by the Habitats Directive 1992 and the Wild Birds Directive 2009, should not be more turned into more than 5% agricultural area. The second main part, also carried out by the EAGF, is 'market measures'. Under the Agricultural Products Regulation 2013 certain crops and meat are eligible for purchase by member state authorities, to be 'stored by them until disposed of', with extra aid for storage.
=== Public security === The Federal Government presented a proposed constitutional amendment (PEC) aimed at modernizing and integrating public security in the country. The initiative, led by the ministry of justice and public security, Ricardo Lewandowski, seeks to strengthen the fight against organized crime and improve cooperation among the Union, states and municipalities. Among the main points are the creation of a Unified Public Security System (SUSP) with constitutional status, the expansion of the responsibilities of the Federal Police and the Federal Highway Police – which would be renamed the Federal Ostensive Police – and the consolidation of permanent financial instruments, such as the National Public Security and Penitentiary Policy Fund, guaranteeing stable resources for the sector. The government argues that the proposal does not remove the autonomy of the states, but seeks to promote greater coordination and efficiency in police action, especially in the face of the advance of criminal factions operating beyond state borders. Even so, the text faces resistance from sectors of the right and the opposition. Despite the criticism, the Ministry of Justice states that the proposal was built in dialogue with governors and specialists, and that it represents an effort to make the fight against crime more integrated, technological and effective throughout the national territory.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.